Skip to content
← All treatment topics

TREATMENT READING

Childhood Pleuropulmonary Blastoma

Source sections for this topic, with the original link and date. Patient and professional reading are labelled separately.

Not medical advice · Not a complete treatment or trial directory

Made by Triangle.

Selected text from the National Cancer Institute, with the original link and date. Made by Triangle. This page is not an NCI PDQ summary. Source topics may be broader than an individual diagnosis.

Health professional

Treatment of Childhood Pleuropulmonary Blastoma

Source: Childhood Pleuropulmonary Blastoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 3, 2025. Captured 2026-09-09.

There are no standard treatment options for childhood pleuropulmonary blastoma. Current treatment regimens for these rare tumors have been informed by consensus opinion. The European Cooperative Study Group for Pediatric Rare Tumors within the PARTNER project (Paediatric Rare Tumours Network–European Registry) published comprehensive recommendations for the diagnosis and treatment of pleuropulmonary blastoma in children and adolescents.[1]

Sources: 1

Treatment options for childhood pleuropulmonary blastoma include the following:

Surgery.

Adjuvant chemotherapy.

A complete surgical resection is required for cure.[2]

Sources: 2

Data from the International Pleuropulmonary Blastoma Registry and the European Cooperative Study Group for Pediatric Rare Tumors suggest that adjuvant chemotherapy may reduce the risk of recurrence.[3]; [4][Level of evidence C1] Responses to chemotherapy have been reported with agents similar to those used for the treatment of rhabdomyosarcoma.[3-5]

Sources: 3 · 4 · Level of evidence C1 · 3 · 5

Some general treatment considerations from the International Pleuropulmonary Blastoma Registry, according to subtype, are discussed below.[3,6]

Sources: 3 · 6

This page is made by Triangle. The reading above is selected source text, not a treatment recommendation, and it is not medical advice.

Health professional · Treatment of Childhood Pleuropulmonary Blastoma

Type I and Type Ir

Source: Childhood Pleuropulmonary Blastoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 3, 2025. Captured 2026-09-09.

Surgery is the treatment of choice for patients with Type I and Type Ir pleuropulmonary blastoma. In the International Pleuropulmonary Blastoma Registry series, the 5-year disease-free survival (DFS) and overall survival (OS) rates were 90% and 98%, respectively, for Type I, and 96% and 100%, respectively, for Type Ir. Approximately 10% of cases progressed to Type II or Type III after surgery. However, adjuvant chemotherapy has been used in almost 40% of patients with Type I disease, and it may be useful for patients at increased risk of recurrence or progression.[3,4,7]

Sources: 3 · 4 · 7

The International Pleuropulmonary Blastoma/DICER1 Registry reported that between 2006 and 2022, there were 205 children who had centrally reviewed Type I or Type Ir pleuropulmonary blastoma. Of these children, 39% with Type I and 5% with Type Ir received chemotherapy.[7]

Sources: 7

Patient outcomes were favorable, although 11 children (9 with Type I and 2 with Type Ir) experienced progression to Type II or III (n = 8) or regrowth of Type I at the surgical site (n = 3). None of these 11 children received chemotherapy before progression.

The combination of age and cyst size was more useful than either factor alone in predicting whether a particular lesion was Type I or Type Ir.

Health professional · Treatment of Childhood Pleuropulmonary Blastoma

Type II and Type III

Source: Childhood Pleuropulmonary Blastoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 3, 2025. Captured 2026-09-09.

For patients with Type II and Type III pleuropulmonary blastoma, a multimodal sarcoma treatment approach is recommended. This approach usually includes rhabdomyosarcoma regimens and either upfront or delayed surgery.[3,4,8] Anthracycline-containing regimens appear to be the most effective.[4]

Sources: 3 · 4 · 8 · 4

In the Pleuropulmonary Blastoma Registry series, the 5-year DFS and OS rates were 59% and 71%, respectively, for Type II, and 37% and 53%, respectively, for Type III.[3] In this group of patients, approximately 50% of relapses occurred in the brain.[3]

Sources: 3 · 3

The International Pleuropulmonary Blastoma/DICER1 Registry reported the outcomes of children with Type II and Type III pleuropulmonary blastoma whose first treatment was ifosfamide, vincristine, dactinomycin, and doxorubicin (IVADo). From 1987 to 2021, 314 children with centrally confirmed Type II and Type III pleuropulmonary blastoma who received upfront chemotherapy were enrolled, 132 of whom (75 with Type II and 57 with Type III) received IVADo chemotherapy.[9]

Sources: 9

Adjusted analyses suggested improved OS for children treated with IVADo, compared with historical controls, with an estimated hazard ratio (HR) of 0.65 (95% confidence interval [CI], 0.39–1.08).

Compared with localized disease, distant metastasis at diagnosis was associated with worse pleuropulmonary blastoma event-free survival and OS, with HRs of 4.23 (95% CI, 2.42–7.38) and 4.69 (95% CI, 2.50–8.80), respectively.

The role of radiation therapy is not well defined. While the use of radiation did not impact survival in the International Pleuropulmonary Blastoma Registry series, only 20% of patients with Type II and Type III received it.[3]

Sources: 3

Health professional

Treatment of Progressive or Recurrent Pleuropulmonary Blastoma

Source: Childhood Pleuropulmonary Blastoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 3, 2025. Captured 2026-09-09.

A retrospective review included 35 children with Type II or Type III pleuropulmonary blastoma and progressive or recurrent disease who were registered in national and European databases and trials (2000–2018).[1] Patients had a median age of 3.9 years (range, 0.5–17.8 years).

Sources: 1

The median time to progression was 0.58 years (range, 0.02–1.27 years) from diagnosis despite surgery, chemotherapy (n = 9), and radiation therapy (n = 1). All of these patients died.

Patients were diagnosed with recurrent disease at a median age of 4.3 years (range, 1.7–15.1 years) and had a median delay to relapse of 1.03 years (range, 0.03–2.95 years).

Recurrent disease occurred locally (n = 12), in combined sites (locally and metastatic) (n = 1), and in metastatic sites (n = 13), including the central nervous system (n = 11) and unspecified sites (n = 2).

The 5-year event-free survival rate and overall survival (OS) rates for patients with recurrent disease were both 37% (± 19%; 95% confidence interval).

Local therapy (surgery and radiation therapy) had a favorable impact on OS (P = .03 and .02, respectively).

Health professional

Treatment Options Under Clinical Evaluation for Childhood Pleuropulmonary Blastoma

Source: Childhood Pleuropulmonary Blastoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 3, 2025. Captured 2026-09-09.

Information about National Cancer Institute (NCI)–supported clinical trials can be found on the NCI website. For information about clinical trials sponsored by other organizations, see the ClinicalTrials.gov website.

Sources: NCI website · ClinicalTrials.gov website

Health professional

Special Considerations for the Treatment of Children With Cancer

Source: Childhood Pleuropulmonary Blastoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 3, 2025. Captured 2026-09-09.

Cancer in children and adolescents is rare, although the overall incidence has slowly increased since 1975.[1] Children and adolescents with cancer should be referred to medical centers that have a multidisciplinary team of cancer specialists with experience treating the cancers that occur during childhood and adolescence. This multidisciplinary team approach incorporates the skills of the following pediatric specialists and others to ensure that children receive treatment, supportive care, and rehabilitation to achieve optimal survival and quality of life:

Sources: 1

Primary care physicians.

Pediatric surgeons.

Pathologists.

Pediatric radiation oncologists.

Pediatric medical oncologists and hematologists.

Ophthalmologists.

Rehabilitation specialists.

Pediatric oncology nurses.

Social workers.

Child-life professionals.

Psychologists.

Nutritionists.

For specific information about supportive care for children and adolescents with cancer, see the summaries on Supportive and Palliative Care.

Sources: Supportive and Palliative Care

The American Academy of Pediatrics has outlined guidelines for pediatric cancer centers and their role in the treatment of children and adolescents with cancer.[2] At these centers, clinical trials are available for most types of cancer that occur in children and adolescents, and the opportunity to participate is offered to most patients and their families. Clinical trials for children and adolescents diagnosed with cancer are generally designed to compare potentially better therapy with current standard therapy. Other types of clinical trials test novel therapies when there is no standard therapy for a cancer diagnosis. Most of the progress in identifying curative therapies for childhood cancers has been achieved through clinical trials. Information about ongoing clinical trials is available from the NCI website.

Sources: 2 · NCI website

Dramatic improvements in survival have been achieved for children and adolescents with cancer. Between 1975 and 2020, childhood cancer mortality decreased by more than 50%.[3-5] Childhood and adolescent cancer survivors require close monitoring because side effects of cancer therapy may persist or develop months or years after treatment. For information about the incidence, type, and monitoring of late effects in childhood and adolescent cancer survivors, see Late Effects of Treatment for Childhood Cancer.

Sources: 3 · 5 · Late Effects of Treatment for Childhood Cancer

Childhood cancer is a rare disease, with about 15,000 cases diagnosed annually in the United States in individuals younger than 20 years.[6] The U.S. Rare Diseases Act of 2002 defines a rare disease as one that affects populations smaller than 200,000 people in the United States. Therefore, all pediatric cancers are considered rare.

Sources: 6 · Rare Diseases Act of 2002

The designation of a rare tumor is not uniform among pediatric and adult groups. In adults, rare cancers are defined as those with an annual incidence of fewer than six cases per 100,000 people. They account for up to 24% of all cancers diagnosed in the European Union and about 20% of all cancers diagnosed in the United States.[7,8] In children and adolescents, the designation of a rare tumor is not uniform among international groups, as follows:

Sources: 7 · 8

A consensus effort between the European Union Joint Action on Rare Cancers and the European Cooperative Study Group for Rare Pediatric Cancers estimated that 11% of all cancers in patients younger than 20 years could be categorized as very rare. This consensus group defined very rare cancers as those with annual incidences of fewer than two cases per 1 million people. However, three additional histologies (thyroid carcinoma, melanoma, and testicular cancer) with incidences of more than two cases per 1 million people were also included in the very rare group due to a lack of knowledge and expertise in the management of these tumors.[9]

Sources: 9

The Children's Oncology Group defines rare pediatric cancers as those listed in the International Classification of Childhood Cancer subgroup XI, which includes thyroid cancers, melanomas and nonmelanoma skin cancers, and multiple types of carcinomas (e.g., adrenocortical carcinomas, nasopharyngeal carcinomas, and most adult-type carcinomas such as breast cancers and colorectal cancers).[10] These diagnoses account for about 5% of the cancers diagnosed in children aged 0 to 14 years and about 27% of the cancers diagnosed in adolescents aged 15 to 19 years.[4] Most cancers in subgroup XI are either melanomas or thyroid cancers, with other cancer types accounting for only 2% of the cancers diagnosed in children aged 0 to 14 years and 9.3% of the cancers diagnosed in adolescents aged 15 to 19 years.

Sources: 10 · 4

These rare cancers are extremely challenging to study because of the relatively few patients with any individual diagnosis, the predominance of rare cancers in the adolescent population, and the small number of clinical trials for adolescents with rare cancers.

Information about these tumors may also be found in sources relevant to adults with cancer.

For patients

Types of treatment for pleuropulmonary blastoma

Source: Pleuropulmonary Blastoma (PDQ®)–Patient Version, National Cancer Institute.

Source updated: May 8, 2025. Captured 2026-09-09.

For patients · Types of treatment for pleuropulmonary blastoma

Who treats children with pleuropulmonary blastoma?

Source: Pleuropulmonary Blastoma (PDQ®)–Patient Version, National Cancer Institute.

Source updated: May 8, 2025. Captured 2026-09-09.

A pediatric oncologist, a doctor who specializes in treating children with cancer, oversees treatment of pleuropulmonary blastoma. The pediatric oncologist works with other health care providers who are experts in treating children with cancer and also specialize in certain areas of medicine. Other specialists may include:

pediatrician

Sources: pediatrician

pediatric surgeon

Sources: pediatric surgeon

pathologist

Sources: pathologist

pediatric nurse specialist

Sources: pediatric nurse specialist

social worker

Sources: social worker

rehabilitation specialist

Sources: rehabilitation specialist

psychologist

Sources: psychologist

child-life specialist

Sources: child-life specialist

fertility specialist

Sources: fertility specialist

There are different types of treatment for children with pleuropulmonary blastoma. You and your child's care team will work together to decide treatment. Many factors will be considered, such as where the cancer is located and your child's age and overall health.

Your child's treatment plan will include information about the tumor, the goals of treatment, treatment options, and the possible side effects. It will be helpful to talk with your child's care team before treatment begins about what to expect. For help every step of the way, visit our booklet, Children with Cancer: A Guide for Parents.

Sources: Children with Cancer: A Guide for Parents

Types of treatment your child might have include:

For patients · Types of treatment for pleuropulmonary blastoma

Surgery

Source: Pleuropulmonary Blastoma (PDQ®)–Patient Version, National Cancer Institute.

Source updated: May 8, 2025. Captured 2026-09-09.

For all types of pleuropulmonary blastoma, surgery is done to remove the whole lobe of the lung with cancer. Chemotherapy may be given to shrink the tumor before surgery for patients with Types II or III pleuropulmonary blastoma.

For patients · Types of treatment for pleuropulmonary blastoma

Chemotherapy

Source: Pleuropulmonary Blastoma (PDQ®)–Patient Version, National Cancer Institute.

Source updated: May 8, 2025. Captured 2026-09-09.

Chemotherapy (also called chemo) uses drugs to stop the growth of cancer cells. Chemotherapy either kills the cancer cells or stops them from dividing. Chemotherapy may be given alone or with other types of treatment. Chemotherapy for pleuropulmonary blastoma is injected into a vein. When given this way, the drugs enter the bloodstream and can reach cancer cells throughout the body.

Chemotherapy drugs used alone or in combination to treat pleuropulmonary blastoma include:

dactinomycin

Sources: dactinomycin

doxorubicin

Sources: doxorubicin

ifosfamide

Sources: ifosfamide

vincristine

Sources: vincristine

Other chemotherapy drugs not listed here may also be used.

Learn more about Chemotherapy to Treat Cancer.

Sources: Chemotherapy to Treat Cancer

For patients · Types of treatment for pleuropulmonary blastoma

Clinical trials

Source: Pleuropulmonary Blastoma (PDQ®)–Patient Version, National Cancer Institute.

Source updated: May 8, 2025. Captured 2026-09-09.

For some children, joining a clinical trial may be an option. There are different types of clinical trials for childhood cancer. For example, a treatment trial tests new treatments or new ways of using current treatments. Supportive care and palliative care trials look at ways to improve quality of life, especially for those who have side effects from cancer and its treatment.

You can use the clinical trial search to find NCI-supported cancer clinical trials accepting participants. The search allows you to filter trials based on the type of cancer, your child's age, and where the trials are being done. Clinical trials supported by other organizations can be found on the ClinicalTrials.gov website.

Sources: clinical trial search · ClinicalTrials.gov

Learn more about clinical trials, including how to find and join one, at Clinical Trials Information for Patients and Caregivers.

Sources: Clinical Trials Information for Patients and Caregivers

For patients · Types of treatment for pleuropulmonary blastoma

Treatment of pleuropulmonary blastoma

Source: Pleuropulmonary Blastoma (PDQ®)–Patient Version, National Cancer Institute.

Source updated: May 8, 2025. Captured 2026-09-09.

Treatment of pleuropulmonary blastoma may include:

For Type I and Type Ir pleuropulmonary blastoma, surgery is done to remove the whole lobe of the lung with cancer.

For Type II and Type III pleuropulmonary blastoma, surgery is done to remove the whole lobe of the lung with cancer. Chemotherapy may be given before surgery to shrink the tumor.

If the cancer comes back after treatment, your child's doctor will talk with you about what to expect and possible next steps. There might be treatment options that may shrink the cancer or control its growth. If there are no treatments, your child can receive care to control symptoms from cancer so they can be as comfortable as possible.

For patients

Side effects and late effects of treatment

Source: Pleuropulmonary Blastoma (PDQ®)–Patient Version, National Cancer Institute.

Source updated: May 8, 2025. Captured 2026-09-09.

Cancer treatments can cause side effects. Which side effects your child might have depends on the type of treatment they receive, the dose, and how their body reacts. Talk with your child's treatment team about which side effects to look for and ways to manage them.

To learn more about side effects that begin during treatment for cancer, visit Side Effects.

Sources: side effects · Side Effects

Problems from cancer treatment that begin 6 months or later after treatment and continue for months or years are called late effects. Late effects of cancer treatment may include:

physical problems

changes in mood, feelings, thinking, learning, or memory

second cancers (new types of cancer) or other conditions

Some late effects may be treated or controlled. It is important to talk with your child's doctors about the possible late effects caused by some treatments.

Disease and treatment settings

Childhood Pleuropulmonary Blastoma

Disease and treatment setting

Pleuropulmonary Blastoma in children and adolescents

recurrent Childhood Pleuropulmonary Blastoma

Disease and treatment setting

Treatment of Progressive or Recurrent Pleuropulmonary Blastoma